Adrian S. Ray
41Patents
24h-index
68Co-inventors
88Inventor score
Filing activity: Feb 5, 2002 → Apr 5, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7973013B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | Chemistry; Metallurgy | 107 | Active |
| US8415308B2 | 1′-substituted-carba-nucleoside prodrugs for antiviral treatment | Chemistry; Metallurgy | 92 | Active |
| US8889159B2 | Compositions and methods for treating hepatitis C virus | Human Necessities | 92 | Active |
| US8455451B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | Human Necessities | 88 | Active |
| US7452901B2 | Anti-cancer phosphonate analogs | Chemistry; Metallurgy | 69 | Expired |
| US7645747B2 | Therapeutic phosphonate compounds | Chemistry; Metallurgy | 57 | Expired |
| US9724360B2 | Methods for treating Filoviridae virus infections | Emerging Cross-Sectional Technologies | 47 | Active |
| US8022083B2 | Antiviral phosphonate analogs | Emerging Cross-Sectional Technologies | 44 | Active |
| US10251904B2 | Methods for treating arenaviridae and coronaviridae virus infections | Human Necessities | 43 | Active |
| US9949994B2 | Methods for treating Filoviridae virus infections | Emerging Cross-Sectional Technologies | 42 | Active |
| US7871991B2 | Phosphonate analogs of HIV inhibitor compounds | Chemistry; Metallurgy | 41 | Active |
| US9393256B2 | Methods for treating HCV | Human Necessities | 40 | Active |
| US9452154B2 | Methods for treating HCV | Human Necessities | 39 | Active |
| US8329926B2 | Antiviral compounds | Chemistry; Metallurgy | 38 | Active |
| US10065958B2 | Methods and compounds for treating Paramyxoviridae virus infections | Emerging Cross-Sectional Technologies | 37 | Active |
| US9549941B2 | Compositions and methods for treating hepatitis C virus | Human Necessities | 37 | Active |
| US8318701B2 | Phosphonate analogs of HIV inhibitor compounds | Chemistry; Metallurgy | 36 | Active |
| US10251898B2 | Methods for treating Filoviridae virus infections | Emerging Cross-Sectional Technologies | 35 | Active |
| US8871785B2 | Antiviral phosphonate analogs | Emerging Cross-Sectional Technologies | 33 | Active |
| US10695361B2 | Methods for treating arenaviridae and coronaviridae virus infections | Human Necessities | 31 | Active |
| US11007208B2 | Methods for treating arenaviridae and coronaviridae virus infections | Human Necessities | 27 | Active |
| US10696679B2 | Methods and compounds for treating paramyxoviridae virus infections | Emerging Cross-Sectional Technologies | 27 | Active |
| US10695357B2 | Methods for treating filoviridae virus infections | Emerging Cross-Sectional Technologies | 27 | Active |
| US9139604B2 | Antiviral phosphonate analogs | Emerging Cross-Sectional Technologies | 26 | Active |
| US7429565B2 | Antiviral phosphonate analogs | Emerging Cross-Sectional Technologies | 24 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.